Peng Xu-Ting, Cai Zhu-Hua, Shen Jie, Zhu Hai-Yan
Department of Gynecology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Department of Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Int J Womens Health. 2025 Apr 7;17:973-982. doi: 10.2147/IJWH.S507845. eCollection 2025.
To explore the application value of low molecular weight heparin combined with heparin in patients with chorionic bump in early pregnancy.
This retrospective study collected 86 cases of patients with early pregnancy complicated by chorionic bump treated in our hospital from January 2020 to February 2022. According to the treatment methods, the patients were divided into the combined treatment group (n=41) and the control group (n=45). Patients in the combined treatment group were treated with oral prednisone combined with low molecular weight heparin injection, while patients in the control group received no additional treatment. The changes and differences in chorionic size, serum hormone levels, and uterine artery blood flow parameters before treatment and at 1 month and 2 months after treatment were compared between the two groups. The pregnancy outcomes and adverse reaction rates were also analyzed.
At 1 month and 2 months after treatment, the average size of the chorionic bump in the combined treatment group was significantly smaller than before treatment and the control group (P<0.05). Two months after treatment, the average levels of E2, P, and LH in the combined treatment group were significantly higher, and the average FSH level was significantly lower than those before treatment and in the control group (P<0.05). At 1 month and 2 months after treatment, the average RI in the combined treatment group was significantly lower than before treatment and the control group, and although the average S/D ratio was higher than before treatment, it was still lower than that of the control group (P<0.05). The incidence of adverse pregnancy outcomes in the combined treatment group was significantly lower than that in the control group (χ²/P=5.469/0.019). There was no significant difference in the incidence of adverse reactions between the two groups (χ²/P=0.613/0.434).
Prednisone combined with low molecular weight heparin can effectively reduce the size of the chorionic bump, improve uterine artery blood flow parameters, and ultimately lower the risk of adverse pregnancy outcomes in patients with early pregnancy complicated by chorionic bump. This treatment approach has reliable clinical safety and holds potential for broader application in such patients.
探讨低分子肝素联合肝素在早孕期绒毛膜下血肿患者中的应用价值。
本回顾性研究收集了2020年1月至2022年2月在我院治疗的86例早孕期合并绒毛膜下血肿的患者。根据治疗方法，将患者分为联合治疗组（n = 41）和对照组（n = 45）。联合治疗组患者采用口服泼尼松联合低分子肝素注射治疗，而对照组患者未接受额外治疗。比较两组治疗前、治疗后1个月和2个月时绒毛膜大小、血清激素水平及子宫动脉血流参数的变化和差异。同时分析妊娠结局和不良反应发生率。
治疗后1个月和2个月时，联合治疗组绒毛膜下血肿的平均大小明显小于治疗前及对照组（P < 0.05）。治疗后2个月，联合治疗组E2、P和LH的平均水平明显升高，FSH平均水平明显低于治疗前及对照组（P < 0.05）。治疗后1个月和2个月时，联合治疗组的平均RI明显低于治疗前及对照组，虽然平均S/D比值高于治疗前，但仍低于对照组（P < 0.05）。联合治疗组不良妊娠结局的发生率明显低于对照组（χ²/P = 5.469/0.019）。两组不良反应发生率差异无统计学意义（χ²/P = 0.613/0.434）。
泼尼松联合低分子肝素可有效减小早孕期合并绒毛膜下血肿患者的绒毛膜下血肿大小，改善子宫动脉血流参数，最终降低不良妊娠结局的风险。该治疗方法具有可靠的临床安全性，在这类患者中有更广泛应用的潜力。
